Trial Profile
A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Diabetic foot ulcer; Embolism and thrombosis; Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Acronyms FEENICS
- Sponsors Pfizer
- 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
- 28 Apr 2012 Planned patient number for extension trial is 215 as reported by European Clinical Trials Database record (EudraCT2008-001566-90).
- 24 Mar 2011 Actual end date (October 2010) of extension trial (NCT00765063) added as reported by ClinicalTrials.gov